Menu
Not yet recruiting NCT06941935

Etiological Classification-guided Individual Intervention in Primary Hypertension

No phase Interventional Hypertension

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Etiological Classification and Digital Intervention.
Who it may be relevant to
Registry conditions: Hypertension. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Etiological Classification-guided Individual Intervention in Primary Hypertension: An All-comer Registry Study

Overview

Eligible participants will first undergo a 1-week home blood pressure diary and 24-hour ambulatory blood pressure assessment. After a confirmed diagnosis of hypertension, etiological subtyping will be performed. Based on the blood pressure evaluation results and etiological classification, the most appropriate antihypertensive medication will be selected. Simultaneously, a personalized lifestyle prescription will be provided according to the patient's individual circumstances. Following medication initiation, participants will continue to monitor their blood pressure through home diaries. Monthly evaluations will be conducted, and if blood pressure fails to reach the target value, medication adjustments will be made based on the blood pressure diary until target levels are achieved. This regimen will be maintained long-term.

Interventions

  • Other Etiological Classification and Digital Intervention
    Eligible participants will first undergo a 1-week home blood pressure diary and 24-hour ambulatory blood pressure assessment. After a confirmed diagnosis of hypertension, etiological subtyping will be performed. Based on the blood pressure evaluation results and etiological classification, the most appropriate antihypertensive medication will be selected. Simultaneously, a personalized lifestyle prescription will be provided according to the patient's individual circumstances. Following medicati

Primary outcome measures

  • Changes in Blood Pressure Recorded in a 1-Week Home Blood Pressure Diary [Time frame: 3 months following intervention]
Secondary outcome measures (4)
  • Change in 24-hour Ambulatory Blood Pressure Monitoring [Time frame: 1/2/3 months following intervention]
  • Change in Home Blood Pressure Monitoring [Time frame: 1/2 months following intervention]
  • Control Rate [Time frame: 3 months following intervention]
  • Drug adjustment times [Time frame: 3 months following intervention]

Eligibility criteria

Inclusion criteria

  • Age 18-65 years.
  • Diagnosed primary hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg).
  • signed informed consent.

Exclusion criteria

  • Secondary hypertension or arrhythmias affecting blood pressure accuracy (e.g., atrial fibrillation).
  • Comorbidities such as diabetes, chronic kidney disease (eGFR < 30 mL/min/1.73m²), coronary artery disease, heart failure, or serious valvular heart disease.
  • History of stroke or myocardial infarction.
  • Pregnancy, breastfeeding, or planning to become pregnant.
  • Life expectancy < 1 year.
  • Participation in another clinical trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 2 centers
  • Department of Cardiology, Shanghai Tenth People's Hospital — Shanghai
  • Shanghai Tenth People's Hospital — Shanghai

Identifiers

NCT: NCT06941935 · GENESIS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗